SCHEMBL8971

SCHEMBL8971

OB(O)c1cccc(OC(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 6/20 0.58
MGLL Q99685 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
DRD1 P21728 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
GRM4 Q14833 2/20 0.40
MEP1B Q16820 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330776 0.85 ENPP2 (0.55) ENPP2MGLLKDM4EALDH1A1CA1
SCHEMBL7998 0.81 ENPP2 (0.63) ENPP2MGLLKDM4EALDH1A1KMT2A
SCHEMBL14814357 0.80 ENPP2 (0.53) ENPP2MGLLKDM4EALDH1A1CA1
SCHEMBL29955202 0.79 CA1 (0.52) ENPP2MAPTCA1CA2ATM
SCHEMBL2554457 0.78 ENPP2 (0.55) ENPP2MGLLKDM4EALDH1A1CA1
SCHEMBL14814249 0.78 ENPP2 (0.54) ENPP2MGLLKDM4EALDH1A1KMT2A
SCHEMBL14814251 0.78 ENPP2 (0.54) ENPP2MGLLKDM4EALDH1A1KMT2A
SCHEMBL28261 0.77 ENPP2 (0.58) ENPP2MGLLKDM4EALDH1A1CA1
SCHEMBL27921960 0.77 MEP1B (0.43) KDM4EDRD1KMT2AMEN1LMNA
SCHEMBL29957100 0.77 CA1 (0.53) ENPP2KMT2AMEN1MAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2026-04-14 US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 US disclosed
EP-4694893-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME Therapeutics LLC (US) 2026-02-18 EP disclosed
US-20260035364-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2026-02-05 US disclosed
US-12540132-B2 Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2026-02-03 US disclosed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-20260008775-A1 AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION CONVELO THERAPEUTICS, INC. 2026-01-08 US disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-7989449-B2 4,5-dihydro-oxazol-2-yl amine derivatives HOFFMAN-LA ROCHE INC. (US) 2011-08-02 US disclosed
WO-2011072064-A1 S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 WO disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 US disclosed
EP-2245019-A1 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-11-03 EP disclosed
WO-2009103626-A1 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 WO disclosed
US-20090209529-A1 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-20 US disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 ENPP2 2672/4885MGLL 4217/4885KDM4E 147/4885
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 ENPP2 2498/4885MGLL 3734/4885KDM4E 2653/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 ENPP2 2857/4885MGLL 1690/4885KDM4E 2616/4885
US-12540132-B2 Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, ACAT2 ENPP2 1418/4885MGLL 74/4885KDM4E 2967/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ENPP2 1006/4885MGLL 1/4885KDM4E 3565/4885
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 ENPP2 4178/4885MGLL 4663/4885KDM4E 191/4885
US-20090209529-A1 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES BACE2, BACE1, PSEN2 ENPP2 54/4885MGLL 2718/4885KDM4E 2818/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885MGLL 2599/4885KDM4E 2418/4885
US-20260008775-A1 AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION MAG, NR1H3, NR1H2 ENPP2 1534/4885MGLL 323/4885KDM4E 2542/4885
US-20260035364-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES SCN1B, SCN2B, SCN11A ENPP2 4765/4885MGLL 2113/4885KDM4E 952/4885
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, GLP1R ENPP2 1392/4885MGLL 2077/4885KDM4E 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.